Company Profile
Spyre Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- SYRE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
103.42 USD (-0.89%)
Close
Last updated: August 6, 2026
6.01B USD
Market cap
Why the stock is moving
The latest monitored company update is “Spyre Therapeutics Announces Grants of Inducement Awards.” The corresponding closing-price reaction is not yet available.
Company overview
Long-Acting Immunology Antibodies
Spyre Therapeutics develops extended-half-life antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases. Its strategy is to combine established immunology targets with less frequent subcutaneous dosing and, ultimately, multi-mechanism regimens.
SKYLINE IBD Platform
The Phase 2 SKYLINE platform trial evaluates SPY001, SPY002 and SPY003 as monotherapies and in pairwise combinations in ulcerative colitis. The antibodies target α4β7, TL1A and IL-23, respectively, enabling Spyre to compare individual mechanisms and combination effects within one development framework.
SPY001
SPY001 is a high-concentration, half-life-extended α4β7 antibody designed for infrequent maintenance dosing. Initial induction data from SKYLINE supported continued development and provided the first clinical proof of concept for Spyre’s platform.
SKYWAY Rheumatic-Disease Program
The Phase 2 SKYWAY basket trial evaluates the anti-TL1A program SPY072 in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. This trial tests whether the same long-acting immunology approach can extend beyond IBD into multiple rheumatic diseases.
Future catalysts
SKYLINE Part A topline data for SPY002 expected in mid-2026.
SKYLINE Part A topline data for SPY003 expected in the third quarter of 2026.
SKYWAY rheumatoid arthritis proof-of-concept results expected in the third quarter of 2026.
Additional SKYWAY proof-of-concept results expected in the fourth quarter of 2026.
SKYLINE Part B induction data for monotherapies and combinations expected in 2027.
Recent news
- 01
Spyre Therapeutics Announces Grants of Inducement Awards
Source: Spyre Therapeutics, Inc.
- 02
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Source: Spyre Therapeutics, Inc.
- 03
- 04
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
Source: Spyre Therapeutics, Inc.
- 05
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
Source: Spyre Therapeutics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Spyre Therapeutics, Inc. (SYRE)?
Spyre Therapeutics, Inc. (SYRE) most recently closed at 103.42 USD, a -0.89% move versus the previous session.
What is the market cap of Spyre Therapeutics, Inc. (SYRE)?
Spyre Therapeutics, Inc. currently has a market capitalization of 6.01B USD on BioPharmSignal.
What does Spyre Therapeutics, Inc. do?
Long-Acting Immunology Antibodies Spyre Therapeutics develops extended-half-life antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases. Its strategy is to combine established immunology targets with less frequent subcutaneous dosing and, ultimately, multi-mechanism regimens. SKYLINE IBD Platform The Phase 2 SKYLINE...
On which exchange is SYRE stock listed?
Spyre Therapeutics, Inc. (SYRE) is associated with NASDAQ, United States, Biopharma.
What is IL-23?
The antibodies target α4β7, TL1A and IL-23, respectively, enabling Spyre to compare individual mechanisms and combination effects within one development framework.
Which conditions is Spyre Therapeutics, Inc. targeting with IL-23?
Spyre Therapeutics, Inc. is associated with immunology based on its company overview and current catalyst commentary.
How does Spyre Therapeutics, Inc. describe recent progress with IL-23?
SKYLINE Part A topline data for SPY002 expected in mid-2026. SKYLINE Part A topline data for SPY003 expected in the third quarter of 2026. SKYWAY rheumatoid arthritis proof-of-concept results expected in the third quarter of 2026. Additional SKYWAY proof-of-concept results expected in the fourth quarter of 2026. SKYLINE Part B induction data for...
What is proof-of-concept?
SKYWAY rheumatoid arthritis proof-of-concept results expected in the third quarter of 2026.